$1.60
-0.12-6.98%
At close: -
$1.60
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
TScan Therapeutics Analyst Ratings and Price Targets | NASDAQ:TCRX | Benzinga
TScan Therapeutics Inc has a consensus price target of $9.83 based on the ratings of 6 analysts. The high is $15 issued by HC Wainwright & Co. on March 6, 2025. The low is $3 issued by Barclays on March 7, 2025. The 3 most-recent analyst ratings were released by Needham, Morgan Stanley, and Barclays on April 8, 2025, March 14, 2025, and March 7, 2025, respectively. With an average price target of $7.33 between Needham, Morgan Stanley, and Barclays, there's an implied 358.33% upside for TScan Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Needham
Morgan Stanley
Barclays
HC Wainwright & Co.
Wedbush
1calculated from analyst ratings
Analyst Ratings for TScan Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/08/2025 | Buy Now | 462.5% | Needham | Gil Blum51% | $9 → $9 | Reiterates | Buy → Buy | Get Alert |
| 03/14/2025 | Buy Now | 525% | Morgan Stanley | Maxwell Skor9% | → $10 | Assumes | → Overweight | Get Alert |
| 03/07/2025 | Buy Now | 87.5% | Barclays | Peter Lawson42% | $14 → $3 | Maintains | Overweight | Get Alert |
| 03/06/2025 | Buy Now | 837.5% | HC Wainwright & Co. | Andrew Fein56% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 03/05/2025 | Buy Now | 462.5% | Needham | Gil Blum51% | $11 → $9 | Maintains | Buy | Get Alert |
| 12/11/2024 | Buy Now | 837.5% | HC Wainwright & Co. | Andrew Fein56% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 12/11/2024 | Buy Now | 587.5% | Needham | Gil Blum51% | $11 → $11 | Reiterates | Buy → Buy | Get Alert |
| 11/15/2024 | Buy Now | 837.5% | HC Wainwright & Co. | Andrew Fein56% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 11/12/2024 | Buy Now | 587.5% | Needham | Gil Blum51% | $11 → $11 | Reiterates | Buy → Buy | Get Alert |
| 11/06/2024 | Buy Now | 587.5% | Needham | Gil Blum51% | $11 → $11 | Reiterates | Buy → Buy | Get Alert |
| 08/13/2024 | Buy Now | 525% | Wedbush | David Nierengarten63% | $10 → $10 | Reiterates | Outperform → Outperform | Get Alert |
| 08/13/2024 | Buy Now | 837.5% | HC Wainwright & Co. | Andrew Fein56% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 08/12/2024 | Buy Now | 587.5% | Needham | Gil Blum51% | $11 → $11 | Reiterates | Buy → Buy | Get Alert |
| 06/04/2024 | Buy Now | 837.5% | HC Wainwright & Co. | Andrew Fein56% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2024 | Buy Now | 650% | BTIG | Justin Zelin41% | → $12 | Initiates | → Buy | Get Alert |
| 05/14/2024 | Buy Now | 837.5% | HC Wainwright & Co. | Andrew Fein56% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 05/13/2024 | Buy Now | 587.5% | Needham | Gil Blum51% | → $11 | Reiterates | Buy → Buy | Get Alert |
| 04/23/2024 | Buy Now | 525% | Wedbush | David Nierengarten63% | $10 → $10 | Reiterates | Outperform → Outperform | Get Alert |
| 03/07/2024 | Buy Now | 837.5% | HC Wainwright & Co. | Andrew Fein56% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 03/07/2024 | Buy Now | 462.5% | Barclays | Peter Lawson42% | $7 → $9 | Maintains | Overweight | Get Alert |
| 02/01/2024 | Buy Now | 462.5% | Wedbush | David Nierengarten63% | $9 → $9 | Reiterates | Outperform → Outperform | Get Alert |
| 08/14/2023 | Buy Now | 837.5% | HC Wainwright & Co. | Andrew Fein56% | → $15 | Reiterates | Buy → Buy | Get Alert |
| 06/22/2023 | Buy Now | 400% | Wedbush | David Nierengarten63% | → $8 | Initiates | → Outperform | Get Alert |
| 05/18/2023 | Buy Now | 837.5% | HC Wainwright & Co. | Andrew Fein56% | → $15 | Reiterates | Buy → Buy | Get Alert |
| 05/11/2023 | Buy Now | 837.5% | HC Wainwright & Co. | Andrew Fein56% | → $15 | Reiterates | Buy → Buy | Get Alert |
| 03/09/2023 | Buy Now | 837.5% | HC Wainwright & Co. | Andrew Fein56% | → $15 | Reiterates | → Buy | Get Alert |
| 05/10/2022 | Buy Now | 837.5% | HC Wainwright & Co. | Andrew Fein56% | $21 → $15 | Maintains | Buy | Get Alert |
FAQ
What is the target price for TScan Therapeutics (TCRX) stock?
The latest price target for TScan Therapeutics (NASDAQ:TCRX) was reported by Needham on April 8, 2025. The analyst firm set a price target for $9.00 expecting TCRX to rise to within 12 months (a possible 462.50% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for TScan Therapeutics (TCRX)?
The latest analyst rating for TScan Therapeutics (NASDAQ:TCRX) was provided by Needham, and TScan Therapeutics reiterated their buy rating.
When was the last upgrade for TScan Therapeutics (TCRX)?
There is no last upgrade for TScan Therapeutics
When was the last downgrade for TScan Therapeutics (TCRX)?
There is no last downgrade for TScan Therapeutics.
When is the next analyst rating going to be posted or updated for TScan Therapeutics (TCRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TScan Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TScan Therapeutics was filed on April 8, 2025 so you should expect the next rating to be made available sometime around April 8, 2026.
Is the Analyst Rating TScan Therapeutics (TCRX) correct?
While ratings are subjective and will change, the latest TScan Therapeutics (TCRX) rating was a reiterated with a price target of $9.00 to $9.00. The current price TScan Therapeutics (TCRX) is trading at is $1.60, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
